CRO CONSULTING SERVICES

Physiogenex provides unique CRO consulting services in order to help our clients in their drug development strategy. This service helps to reduce time and cost, and ensures the successful launch of new therapies. We offer over 15 years of experience in developing drugs targeting obesity, type 2 diabetes, dyslipidaemia, inflammation, diabetic nephropathy, NASH/MASH, fibrosis and cardiovascular complications.

For each consulting request, we provide a customized and personalized service with:

• A complete and topic-related literature search,
• A thorough analysis of available data on the drug or therapeutic target,
• Our interpretation and recommendations for a successful drug development

The CRO consulting services include a continuous interaction between Physiogenex’s experts and our clients with phone conferences, on-site face-to-face meetings, and a complete consulting report including scientific references.

The word of the CEO

Thierry Sulpice, PhD
CEO, CSO, Founder of Physiogenex and Member of the Scientific Advisory Board

Et Epigonus quidem amictu tenus philosophus, ut apparuit, prece frustra temptata, sulcatis lateribus mortisque metu admoto turpi confessione cogitatorum socium, quae nulla erant, fuisse firmavit cum nec vidisset quicquam nec audisset penitus expers forensium rerum; Eusebius vero obiecta fidentius negans, suspensus in eodem gradu constantiae stetit latrocinium illud esse, non iudicium clamans. Et Epigonus quidem amictu tenus philosophus, ut apparuit, prece frustra temptata, sulcatis lateribus mortisque metu admoto turpi confessione cogitatorum socium, quae nulla erant, fuisse firmavit cum nec vidisset quicquam nec audisset penitus expers forensium rerum; Eusebius vero obiecta fidentius negans, suspensus in eodem gradu constantiae stetit latrocinium illud esse, non iudicium clamans.